{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:00:00Z","timestamp":1792083600838,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.fjurol.2026.103229","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:21:03Z","timestamp":1790688063000},"page":"103229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential intravesical gemcitabine\u2013docetaxel after BCG failure non-muscle invasive bladder cancer: Oncological outcomes and safety profile"],"prefix":"10.1016","volume":"36","author":[{"given":"Albane","family":"Massiet du Biest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Etienne","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2026.103229_bib0155","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2026.04.009","article-title":"EAU guidelines on nonmuscle-invasive bladder cancer (TaT1 and CIS) - A summary of the 2026 guidelines update","volume":"90","author":"Gontero","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0160","doi-asserted-by":"crossref","first-page":"106.e1","DOI":"10.1016\/j.urolonc.2021.10.008","article-title":"Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; a comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model","volume":"40","author":"Dovey","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0165","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC Nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0175","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1001\/jama.2022.7393","article-title":"Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial","volume":"327","author":"Catto","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.fjurol.2026.103229_bib0180","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bju.16610","article-title":"Long-term quality of life in patients with bladder cancer following radical cystectomy","volume":"135","author":"Akdemir","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2026.103229_bib0185","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0195","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for Bacillus Calmette-Gu\u00e9rin-Unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0200","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MOU.0000000000001065","article-title":"Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"33","author":"Kawada","year":"2023","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.fjurol.2026.103229_bib0210","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.fjurol.2026.103229_bib0215","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bju.16645","article-title":"Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results","volume":"135","author":"Scilipoti","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2026.103229_bib0220","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1159\/000524098","article-title":"Quality of life, efficacy, and safety of sequential intravesical gemcitabine+docetaxel versus BCG for non-muscle invasive urinary bladder cancer: a pilot study","volume":"106","author":"Pareek","year":"2022","journal-title":"Urol Int"},{"key":"10.1016\/j.fjurol.2026.103229_bib0225","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.70126","article-title":"Quality of life and cost-effectiveness of intravesical gemcitabine\/docetaxel vs BCG in BCG-na\u00efve non-muscle-invasive bladder cancer","volume":"137","author":"Srivastava","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2026.103229_bib0230","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0235","doi-asserted-by":"crossref","first-page":"458.e1","DOI":"10.1016\/j.urolonc.2023.06.018","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0240","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0245","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euo.2024.12.005","article-title":"Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Gu\u00e9rin in patients with bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","volume":"8","author":"Taylor","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0250","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in Bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0255","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-23-0354","article-title":"A phase II study of durvalumab for Bacillus Calmette-Guerin (BCG) unresponsive urothelial carcinoma in situ of the bladder","volume":"29","author":"Li","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.fjurol.2026.103229_bib0260","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS593","article-title":"SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Gu\u00e9rin who are ineligible for or decline radical cystectomy","volume":"40","author":"Van Der Heijden","year":"2022","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.fjurol.2026.103229_bib0265","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1158\/1078-0432.CCR-25-1231","article-title":"FDA approval summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situ","volume":"31","author":"Heiss","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.fjurol.2026.103229_bib0270","doi-asserted-by":"crossref","first-page":"62.e13","DOI":"10.1016\/j.urolonc.2021.07.019","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Pijpers","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0275","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1007\/s00345-023-04332-z","article-title":"Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure","volume":"41","author":"Pignot","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0280","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0285","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00345-025-06179-y","article-title":"Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter study","volume":"44","author":"Scilipoti","year":"2026","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0290","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jval.2022.12.005","article-title":"Cost-effectiveness of nadofaragene firadenovec and pembrolizumab in Bacillus Calmette-Gu\u00e9rin immunotherapy unresponsive non-muscle invasive bladder cancer","volume":"26","author":"Joshi","year":"2023","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.fjurol.2026.103229_bib0295","doi-asserted-by":"crossref","first-page":"391.e1","DOI":"10.1016\/j.urolonc.2023.04.005","article-title":"Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: a preliminary cost-effectiveness analysis","volume":"41","author":"Bukavina","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103229_bib0300","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026001609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026001609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:32:47Z","timestamp":1792081967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393026001609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2950393026001609"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103229","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential intravesical gemcitabine\u2013docetaxel after BCG failure non-muscle invasive bladder cancer: Oncological outcomes and safety profile","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103229"}}